Hôpital Saint-Louis, Medical ICU, Paris, France.
J Clin Oncol. 2013 Aug 1;31(22):2810-8. doi: 10.1200/JCO.2012.47.2365. Epub 2013 Jun 10.
PURPOSE Patients with hematologic malignancies are increasingly admitted to the intensive care unit (ICU) when life-threatening events occur. We sought to report outcomes and prognostic factors in these patients. PATIENTS AND METHODS Ours was a prospective, multicenter cohort study of critically ill patients with hematologic malignancies. Health-related quality of life (HRQOL) and disease status were collected after 3 to 6 months. Results Of the 1,011 patients, 38.2% had newly diagnosed malignancies, 23.1% were in remission, and 24.9% had received hematopoietic stem-cell transplantations (HSCT, including 145 allogeneic). ICU admission was mostly required for acute respiratory failure (62.5%) and/or shock (42.3%). On day1, 733 patients (72.5%) received life-supporting interventions. Hospital, day-90, and 1-year survival rates were 60.7%, 52.5%, and 43.3%, respectively. By multivariate analysis, cancer remission and time to ICU admission less than 24 hours were associated with better hospital survival. Poor performance status, Charlson comorbidity index, allogeneic HSCT, organ dysfunction score, cardiac arrest, acute respiratory failure, malignant organ infiltration, and invasive aspergillosis were associated with higher hospital mortality. Mechanical ventilation (47.9% of patients), vasoactive drugs (51.2%), and dialysis (25.9%) were associated with mortality rates of 60.5%, 57.5%, and 59.2%, respectively. On day 90, 80% of survivors had no HRQOL alterations (physical and mental health similar to that of the overall cancer population). After 6 months, 80% of survivors had no change in treatment intensity compared with similar patients not admitted to the ICU, and 80% were in remission. CONCLUSION Critically ill patients with hematologic malignancies have good survival, disease control, and post-ICU HRQOL. Earlier ICU admission is associated with better survival.
当发生危及生命的事件时,患有血液系统恶性肿瘤的患者越来越多地被收入重症监护病房(ICU)。我们旨在报告这些患者的结局和预后因素。
这是一项针对重症血液系统恶性肿瘤患者的前瞻性、多中心队列研究。在 3 至 6 个月后收集与健康相关的生活质量(HRQOL)和疾病状况。
在 1011 例患者中,38.2%为新发恶性肿瘤,23.1%处于缓解期,24.9%接受了造血干细胞移植(HSCT,包括 145 例异基因)。ICU 收治主要是由于急性呼吸衰竭(62.5%)和/或休克(42.3%)。第 1 天,733 例(72.5%)患者接受了生命支持干预。住院、第 90 天和 1 年生存率分别为 60.7%、52.5%和 43.3%。多变量分析显示,癌症缓解和 ICU 入院时间小于 24 小时与住院生存率改善相关。较差的表现状态、Charlson 合并症指数、异基因 HSCT、器官功能障碍评分、心搏骤停、急性呼吸衰竭、恶性器官浸润和侵袭性曲霉菌病与较高的住院死亡率相关。机械通气(47.9%的患者)、血管活性药物(51.2%)和透析(25.9%)的死亡率分别为 60.5%、57.5%和 59.2%。在第 90 天,80%的幸存者 HRQOL 没有改变(身体和心理健康与整体癌症人群相似)。6 个月后,与未收入 ICU 的类似患者相比,80%的幸存者治疗强度没有改变,80%处于缓解期。
患有血液系统恶性肿瘤的重症患者具有良好的生存率、疾病控制和 ICU 后 HRQOL。更早的 ICU 收治与更好的生存率相关。